Halozyme Therapeutics (HALO) Liabilities and Shareholders Equity (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $2.7 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $2.7 billion, up 21.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 billion (up 13.49% YoY), and the FY2025 annual result was $2.5 billion, up 22.38% from the prior year.
• Liabilities and Shareholders Equity climbed to $2.7 billion in Q1 2026 per HALO's latest filing, from $2.5 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $2.7 billion in Q1 2026 and troughed at $1.2 billion in Q1 2022.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 73.65% in 2022, then retreated 5.88% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.8 billion in 2022, then declined by 5.88% to $1.7 billion in 2023, then rose by 19.05% to $2.1 billion in 2024, then increased by 22.38% to $2.5 billion in 2025, then grew by 5.84% to $2.7 billion in 2026.
• Business Quant data shows HALO's Liabilities and Shareholders Equity at $2.7 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.2 billion in Q3 2025.